| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| MT2-AF5p |
|
C59H90N22O15 |
1347.48 |
H2N–HHRLHSAPPPQA–OH |
H2N–His–His–Arg–Leu–His–Ser–Ala–Pro–Pro–Pro–Gln–Ala–OH |
12 |
MT2-MMP–targeting peptide |
|
| GE11-CY5 |
|
C81H109N19O20 |
1668.88 |
YHWYGYTPQNVIK |
H2N-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-Val-Ile-Lys(CY5)-OH |
13 |
|
|
| Cys-GE11 |
|
C78H102N18O20S |
1643.84 |
CYHWYGYTPQNVI |
H2N-Cys-Tyr-His-Trp-Tyr-Gly-Tyr-Thr-Pro-Gln-Asn-Val-Ile-OH |
13 |
|
|
| Dcpep |
|
C69H94N18O19 |
1479.42 |
FYPSYHSTPQRP |
H2N-Phe-Tyr-Pro-Ser-Tyr-His-Ser-Thr-Pro-Gln-Arg-Pro-OH |
12 |
|
|
| TfR-T12 |
344618-30-0 |
C71H99N19O15S |
1490.75 |
THRPPMWSPVWP |
H2N-Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro-OH |
12 |
TfR-targeting peptide |
|
| Angiopep-2-Cys |
906480-09-9 |
C107H154N30O32S |
2404.65 |
TFFYGGSRGKRNNFKTEEYC |
H2N-Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Lys-Arg-Asn-Asn-Phe-Lys-Thr-Glu-Glu-Tyr-Cys-OH |
20 |
Brain-targeting peptide |
|
| Cys-Angiopep-2 |
|
C107H154N30O32S |
2404.65 |
CTFFYGGSRGKRNNFKTEEY |
H2N-Cys-Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Lys-Arg-Asn-Asn-Phe-Lys-Thr-Glu-Glu-Tyr-OH |
20 |
Brain-targeting peptide |
|
| CBP4 |
|
C62H98N16O19S1 |
1403.6 |
H2N–KMPKENPSSWLS–OH |
H2N–Lys–Met–Pro–Lys–Glu–Asn–Pro–Ser–Ser–Trp–Leu–Ser–OH |
12 |
CD133 protein–targeting peptide |
|
| EP-100 |
|
C163H243N43O32 |
3316.94 |
H2N–KFAKFAKKFAKFAKKFAKQHWSYGLRPG–OH |
H2N–Lys–Phe–Ala–Lys–Phe–Ala–Lys–Lys–Phe–Ala–Lys–Phe–Ala–Lys–Lys–Phe–Ala–Lys–Gln–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly–OH |
28 |
LHRH receptor–targeting peptide |
|
| YLA peptide |
|
C44H68N14O12S2 |
1049.23 |
H2N–CYLASRVHC–OH |
H2N–Cys–Tyr–Leu–Ala–Ser–Arg–Val–His–Cys–OH |
9 |
LGR5-targeting peptide |
|
| HLRKLRKR |
|
C48H91N21O9 |
— |
H2N–HLRKLRKR–OH |
H2N–His–Leu–Arg–Lys–Leu–Arg–Lys–Arg–OH |
8 |
TREM2-targeting peptide |
|
| LRKLRLRL |
|
C48H94N18O9 |
— |
H2N–LRKLRLRL–OH |
H2N–Leu–Arg–Lys–Leu–Arg–Leu–Arg–Leu–OH |
8 |
TREM2-targeting peptide |
|
| ANYEFSQV |
|
C43H60N10O15 |
956.99 |
H2N–ANYEFSQV–OH |
H2N–Ala–Asn–Tyr–Glu–Phe–Ser–Gln–Val–OH |
8 |
CD38-targeting peptide |
|
| E1-3 |
|
C41H60N10O9 |
836.98 |
H2N–FSRPAFL–OH |
H2N–Phe–Ser–Arg–Pro–Ala–Phe–Leu–OH |
7 |
Medulloblastoma cell–targeting peptide |
|
| T3BP |
|
C142H255N69O36S1 |
3537.05 |
H2N–TRRRRAKRSPKHHSQRARKKNKNCRRHS–OH |
H2N–Thr–Arg–Arg–Arg–Arg–Ala–Lys–Arg–Ser–Pro–Lys–His–His–Ser–Gln–Arg–Ala–Arg–Lys–Lys–Asn–Lys–Asn–Cys–Arg–Arg–His–Ser–OH |
28 |
TGFBR3-targeting peptid |
|
| NG2 binding peptide |
241478-23-9 |
C40H69N15O14S1 |
1016.13 |
H2N–TAASGVRSMH–OH |
H2N–Thr–Ala–Ala–Ser–Gly–Val–Arg–Ser–Met–His–OH |
10 |
NG2 proteoglycan–targeting peptide |
|
| pPB |
|
C35H60N12O13S2 |
921.05 |
H2N–CSRNLIDC–OH |
H2N–Cys–Ser–Arg–Asn–Leu–Ile–Asp–Cys–OH |
8 |
PDGFR-β–targeting peptide |
|
| YGEGTSSFWL |
|
C54H71N11O17 |
1146.21 |
H2N–YGEGTSSFWL–OH |
H2N–Tyr–Gly–Glu–Gly–Thr–Ser–Ser–Phe–Trp–Leu–OH |
10 |
Von Hippel–Lindau (VHL)–targeting peptide |
|
| SSKLRQLLF |
|
C50H86N14O13 |
1091.3 |
H2N–SSKLRQLLF–OH |
H2N–Ser–Ser–Lys–Leu–Arg–Gln–Leu–Leu–Phe–OH |
9 |
Androgen receptor (AR)–targeting peptide |
|
| GX1 |
|
C38H56N10O16S2 |
973.04 |
H2N–CNTGSPYEC–OH |
H2N–Cys–Asn–Thr–Gly–Ser–Pro–Tyr–Glu–Cys–OH |
9 |
Gastric cancer vascular endothelial cell–targeting peptide |
|
